PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling ...

PISCATAWAY, N.J. — Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling its commercial ...

Piscataway, N.J., United States: Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection ...

Greater Effectiveness and Enhanced Safety Profiles of Biosimilars Compared to Their Reference Biologics Increasing Their Adoption Worldwid ...

Q4 2024 Earnings Call Transcript March 10, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

However, the market share in another medicine Pegfilgrastim dropped 760 basis points to 27.5% from Nov-24 to Dec-24, but it is still above 23.1% clocked in Sep-24. “Market share for Trastuzumab ...

UDENYCA® is a pegfilgrastim biosimilar used to reduce the chance of infection in patients with some tumors. Coherus BioSciences, headquartered in Redwood (NYSE:RWT) City, California, is known for ...

Neulasta (pegfilgrastim) is a prescription drug used to help prevent infection from certain types of chemotherapy and to treat radiation sickness. Neulasta can interact with certain other ...